Content about Antiviral drug

January 13, 2014

According to this week's FluView report, overall flu activity continued to be high across the nation, with activity continuing to spread from state to state, the Centers for Disease Control and Prevention reported Friday.

ATLANTA — According to this week's FluView report, overall flu activity continued to be high across the nation, with activity continuing to spread from state to state, the Centers for Disease Control and Prevention reported Friday. Thirty-five states are now experiencing widespread activity, and 20 states are reporting high levels of influenza-like illness. 

November 27, 2013

Treatment of influenza with antiviral medicines like Tamiflu and Relenza may improve survival rates in children, according to a study published Nov. 25 in Pediatrics.

ELK GROVE VILLAGE, Ill. — Treatment of influenza with such antiviral medicines as Tamiflu and Relenza may improve survival rates in children, according to a study published on Nov. 25 in Pediatrics

Researchers from the California Department of Public Health analyzed data abstracted from medical records to characterize the outcomes of pediatric patients hospitalized with the flu between April 3, 2009 and September 30, 2012. 

October 25, 2013

A Food and Drug Administration expert panel has recommended approval for a drug made by Johnson & Johnson for treating hepatitis C, the company said.

NEW YORK — A Food and Drug Administration expert panel has recommended approval for a drug made by Johnson & Johnson for treating hepatitis C, the company said.

J&J subsidiary Janssen Research & Development said the 19-member FDA Antiviral Drugs Advisory Committee voted unanimously to recommend approval for TMC435 (simeprevir), a 150-mg drug meant for administration once per day with the generic antiviral ribavirin and a biotech drug known as an interferon, for treating genotype 1 chronic hepatitis C.

October 24, 2013

An experimental drug under development by Gilead Sciences for hepatitis C is safe and effective when combined with other treatments, according to a review posted on the Food and Drug Administration's website ahead of an expert panel meeting to take place Friday.

NEW YORK — An experimental drug under development by Gilead Sciences for hepatitis C is safe and effective when combined with other treatments, according to a review posted on the Food and Drug Administration's website ahead of an expert panel meeting to take place Friday.

May 6, 2013

An experimental drug regimen under development by AbbVie could change the way hepatitis C is treated, according to a special designation it received from the Food and Drug Administration.

NORTH CHICAGO, Ill. — An experimental drug regimen under development by AbbVie could change the way hepatitis C is treated, according to a special designation it received from the Food and Drug Administration.

February 15, 2013

According to research published in the New England Journal of Medicine, not all respiratory ailments that generate influenza-like symptoms can be attributed to the flu.

BOSTON — According to research published Thursday in the New England Journal of Medicine, not all respiratory ailments that generate influenza-like symptoms can be attributed to the flu. The human metapneumovirus — which is not a strain of influenza, is impervious to antiviral medicines like Tamiflu and does not have an available vaccine according to reports — causes just as many hospitalizations and outpatient visits among children as does the flu. 

September 10, 2012

A drug maker and medical research institute will work together to identify new treatments for bacterial and viral infections.

CAMBRIDGE, Mass. — A drug maker and medical research institute will work together to identify new treatments for bacterial and viral infections.

AstraZeneca and the Broad Institute, owned jointly by Harvard University and MIT, announced Monday that they would collaborate for two years to develop medicines to treat severe infections, saying the identification of high-quality chemicals for the development of new drugs was a significant challenge. The two will use the Broad Institute's collection of 100,000 chemicals known as diversity-oriented synthesis, or DOS compounds.

July 25, 2011

A phrase like “silent killer” sounds creepy enough on its own, but it’s an often-used one for a virus that, according to the Centers for Disease Control and Prevention, infects 1.3% to 1.9% of people in the United States.


A phrase like “silent killer” sounds creepy enough on its own, but it’s an often-used one for a virus that, according to the Centers for Disease Control and Prevention, infects 1.3% to 1.9% of people in the United States.


November 24, 2010

Since the beginning of the HIV/AIDS epidemic in the early 1980s, one of the greatest advances has been antiviral drugs that have helped extend the lives of patients with viral infections.

ST. LOUIS — Since the beginning of the HIV/AIDS epidemic in the early 1980s, one of the greatest advances has been antiviral drugs that have helped extend the lives of patients with viral infections.

October 31, 2010

Drug makers Valeant Pharmaceuticals International and Kadmon Pharmaceuticals will collaborate to develop antiviral drugs for...

March 1, 2010

The market for hepatitis C drugs could get a boost if a clinical trial program...